Addition of high-throughput technologies and expanded pharmacokinetic
services enhances existing support for small molecule drug discovery
WILMINGTON, Mass.--(BUSINESS WIRE)--May 1, 2018--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the expansion of its service capabilities in early discovery
screening. Charles River is the first contract research organization to
offer clients access to Apricot Designs' Dual Arm (ADDA) system for
high-throughput absorption, distribution, metabolism, and excretion
(HT-ADME) to identify potential lead compounds in North America and
Europe. Additionally, the Company has geographically expanded its
pharmacokinetic (PK) capabilities at sites central to major
pharmaceutical and biotechnology hubs.
Early screening provides important insight into a compound’s underlying
biology, and streamlined HT-ADME
and PK technologies are essential components to identifying
promising candidates early in the drug discovery process.
Addition of Apricot Designs’ ADDA System
system is a high-speed autosampler designed for drug discovery that
provides ADME discovery scientists with a fast sample delivery platform
for liquid chromatography/mass spectrometry (LC/MS). Automated
permeability, metabolic stability, and protein binding screening assays
can be rapidly turned around with the ADDA system and a single mass
spectrometer system, saving critical time in the drug discovery process.
Expansion of Pharmacokinetic Capabilities
In both San Francisco and 's-Hertogenbosch, The Netherlands, Charles
River has expanded capabilities and capacity for PK screening, providing
for interactive and collaborative relationships aimed at accelerating
clients’ discovery programs.
Therapeutic-area-agnostic PK services support drug discovery efforts
from the initial PK screening of compounds and lead optimization to
late-stage candidate nomination and Investigational New Drug-enabling
“In early discovery research, screening is an essential component of
any successful program. With access to industry-leading technologies,
we’re able to provide our clients strategic guidance, ultimately
working toward accelerating their programs.” –Birgit Girshick,
Corporate Executive Vice President, Discovery and Safety Assessment,
“The early discovery industry is seeing a marked shift towards a
better understanding of the underlying biology of candidate compounds.
Both HT-ADME and PK technologies are critical to that understanding,
and to developing more successful candidates in early discovery.” –Ian
Waddell, PhD Executive Director, Biology, Charles River
“The ADDA system, Apricot Designs’ dual arm autosampler was designed
with early discovery scientists in mind. It enables seamless
integration with LC/MS systems, accelerating the laboratory research
process and yielding the best results.” –Felix H. Yiu, Founder and
CEO, Apricot Designs, Inc.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501005239/en/
Source: Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
President, Public Relations